Vascular Endothelial Growth Factor 936 C/T Gene Polymorphism in Indonesian Subjects with Diabetic Polyneuropathy


  • Jimmy Barus Department of Neurology, School of Medicine and Health Sciences, Universitas Katolik Indonesia Atma Jaya, Jakarta
  • Ismail Setyopranoto Department of Neurology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta
  • Ahmad Hamim Sadewa Department of Biochemistry, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta
  • Samekto Wibowo Department of Neurology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta



VEGF 936 C/T polymorphism, VEGF-A level, Diabetic polyneuropathy


AIM: This study aimed to confirm the role of f VEGF gene 936 C/T polymorphism and Diabetic Polyneuropathy (DPN) in the Indonesian population as well as to investigate its relationship with VEGF-A level and the role of vascular risk factors.

MATERIAL AND METHODS: This was a cross-sectional study involving 152 subjects. Clinical symptoms and signs of DPN were examined using DNE and DNS scoring followed by nerve conduction study. All subjects underwent anthropometric, clinical examination and laboratory procedures to obtain body mass index, HbA1C level, lipid profile, Polymorphism of +936 C/T VEGF gene (PCR-RFLP technique), and VEGF-A plasma level (ELISA). Statistical analysis using a t-test or Mann-Whitney was performed to assess continuous data and Chi-square for categorical data. Multivariate logistic regressions were also performed to determine the relationship between independent variables and DPN.

RESULTS: Sixty-nine (45.4%) fulfilled the diagnostic criteria of DPN. There was a significant association between CT + TT genotype and DPN (OR 0.35 95%CI 0.16-0.79 p = 0.01). Multivariate logistic regression showed that plasma VEGF-A level (OR = 1.003; 95% CI = 1.000-1.007; p = 0.03), diabetes duration (OR = 1.108; 95% CI = 1.045-1.175; p = 0.001), and CT+TT genotype (OR = 0.347; 95%CI = 0.148-0.817; p = 0.013) were associated with DPN. Sub-group analysis on subjects with HbA1C level ≥7% showed that VEGF-A (OR = 1.011; 95%CI = (1.004-1.017; p = 0.03), diabetes duration (OR = 1.245; 95% CI = 1.117-1.388; p < 0.001), CT + TT genotype (OR = 0.259; 95%CI = 0.074-0.911p = 0.035), with an adition of HDL (OR = 0.916; 95% CI = 0.857-0.978; p = 0.009) were significant predictors of DPN while LDL (OR = 1.017; 95% CI = 1.000-1.035; p = 0.053) acted as modifying factor.

CONCLUSION: It appeared that CT + TT genotype of VEGF +936 gene might act as a protecting factor for DPN while VEGF-A, diabetes duration, HDL, and LDL acted as risk factors especially on subjects with HbA1C level ≥ 7.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Sugimoto K, Murakawa Y, Sima AAF. Diabetic neuropathy–a continuing enigma. Diabetes/metabolism research and reviews. 2000; 16(6):408–433.<408::AID-DMRR158>3.0.CO;2-R

Bhutani J, Bhutani S. Worldwide burden of diabetes. Indian journal of endocrinology and metabolism. 2014; 18(6):868. PMid:25364686 PMCid:PMC4192997

Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacology & Therapeutics. 2008; 120(1):1–34. PMid:18616962 PMCid:PMC4007052

Soewondo P, Soegondo S, Suastika K, Pranoto A, Soeatmadji DW, Tjokroprawiro A. The DiabCare Asia 2008 study–Outcomes on control and complications of type 2 diabetic patients in Indonesia. Medical Journal of Indonesia. 2010; 19(4):235–44.

Deguchi T, Hashiguchi T, Horinouchi S, Uto T, Oku H, Kimura K, et al. Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage. Diabetic Medicine. 2009; 26(3):247–252. PMid:19317819

Zhang X, Sun Z, Jiang H, Song X. Relationship between single nucleotide polymorphisms in the 3'-untranslated region of the vascular endothelial growth factor gene and susceptibility to diabetic peripheral neuropathy in China. Archives of medical science. 2014; 10(5):1028–1034. PMid:25395956 PMCid:PMC4223128

Kim HW, Ko GJ, Kang YS, Lee MH, Song HK, Kim HK, et al. Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients. Nephrology. 2009; 14(7):681–688. PMid:19796028

Yang C-P, Lin C-C, Li C-I, Liu C-S, Lin W-Y, Hwang K-L, et al. Cardiovascular risk factors increase the risks of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus: the Taiwan Diabetes Study. Medicine. 2015; 94(42).

Meijer JW, van Sonderen E, Blaauwwiekel EE, Smit AJ, Groothoff JW, Eisma WH, et al. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care. 2000; 23(6):750–753. PMid:10840990

Meijer J-WG, Bosma E, Lefrandt JD, Links TP, Smit AJ, Stewart RE, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes care. 2003; 26(3):697–701.

Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels G-J, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes/metabolism research and reviews. 2011; 27(7):620–628. PMid:21695763

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. International journal of cancer. 2003; 106(4):468–471. PMid:12845639

rs3025039 (SNP) - Population genetics - Homo sapiens - Ensembl genome browser 92 [Internet]. [cited 2018 Jul 10]. Available from:;r=6:43784299-43785299;v=rs3025039;vdb=variation;vf=2313204

Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B, et al. VEGF gene polymorphism association with diabetic neuropathy. Molecular biology reports. 2010; 37(7):3625–3630. PMid:20352346

Cao C, Ding Q, Lv D, Dong Z, Sun S, Chen Z, et al. Vascular endothelial growth factor genotypes and haplotypes contribute to the susceptibility of obstructive sleep apnea syndrome. PloS one. 2014; 9(12):e114582. PMid:25541696 PMCid:PMC4277275

Elias I, Franckhauser S, Bosch F. New insights into adipose tissue VEGF-A actions in the control of obesity and insulin resistance. Adipocyte. 2013; 2(2):109–112. PMid:23805408 PMCid:PMC3661112

Zacchigna S, Lambrechts D, Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nature Reviews Neuroscience. 2008; 9(3):169. PMid:18253131

Grisold A, Callaghan BC, Feldman EL. Mediators of diabetic neuropathy-is hyperglycemia the only culprit? Current opinion in endocrinology, diabetes, and obesity. 2017; 24(2):103. PMid:28098594 PMCid:PMC5831542

Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nature Reviews Neurology. 2011; 7(10):573. PMid:21912405

Perez-Matos MC, Morales-Alvarez MC, Mendivil CO. Lipids: a suitable therapeutic target in diabetic neuropathy? Journal of diabetes research. 2017; 2017.

Cho YN, Lee KO, Jeong J, Park HJ, Kim S-M, Shin HY, et al. The role of insulin resistance in diabetic neuropathy in Koreans with type 2 diabetes mellitus: a 6-year follow-up study. Yonsei medical journal. 2014; 55(3):700–708. PMid:24719137 PMCid:PMC3990070

Ghisleni MM, Biolchi V, Jordon BC, Rempel C, Genro JP, Pozzobon A. Association study of C936T polymorphism of the VEGF gene and the C242T polymorphism of the p22phox gene with diabetes mellitus type 2 and distal diabetic polyneuropathy. Molecular medicine reports. 2015; 12(3):4626–4633. PMid:26130419



How to Cite

Barus J, Setyopranoto I, Sadewa AH, Wibowo S. Vascular Endothelial Growth Factor 936 C/T Gene Polymorphism in Indonesian Subjects with Diabetic Polyneuropathy. Open Access Maced J Med Sci [Internet]. 2018 Oct. 7 [cited 2024 Jun. 17];6(10):1784-9. Available from:



A - Basic Science

Most read articles by the same author(s)

1 2 > >>